INTRODUCTION

An 80-year-old gentleman with very severe aplastic anemia was treated with standard combination therapy of equine antithymocyte globulin and cyclosporine A. His death shortly after treatment could be attributed to his advanced age, severe pancytopenia at diagnosis, absence of minor paroxysmal nocturnal hemoglobinuria clone, and immunosuppressive therapy-related complications.

Aplastic anemia (AA) is an acquired bone marrow failure syndrome characterized by fatty replacement and diminished production of hematopoietic precursor stem cells of the bone marrow. Immune-mediated destruction of hematopoietic stem cell precursors in AA is triggered by the activated cytotoxic T cells which express a variety of inhibitory cytokines such as interferon-gamma through the Fas-dependent apoptosis pathway. AA demonstrates a bimodal age distribution in which, it occurs most frequently in those aged between 20 and 30 and over 60. AA has an annual incidence of 2 per 1,000,000 population in the West, but it is higher in Asia. The common causes for aplastic anemia are exposure to toxic chemicals such as benzene, certain drugs such as chloramphenicol, ionizing radiation, history of cytotoxic chemotherapy, viral infections, and autoimmune diseases. Most AA diagnosed in the elderly are idiopathic, and they do not exhibit any underlying secondary etiology. Age over 60 years is an important independent risk factor for mortality in AA.

One should consider other possibilities such as myelodysplastic syndrome (MDS), paroxysmal nocturnal hemoglobinuria (PNH), nutritional deficiency, late onset telomeropathy, and delayed onset inherited bone marrow failure syndromes when diagnosing AA in the elderly. Here, we describe a case of idiopathic very severe aplastic anemia in an 80-year-old man who was treated with standard first-line therapy but subsequently succumbed to severe infection.

CASE PRESENTATION

An 80-year-old Chinese gentleman with no known prior medical illness presented to the department of hematology with lethargy, reduced effort tolerance, easy bruising, anorexia, and loss of weight for the past 6 weeks. He has no significant family history. He is a nonsmoker and a teetotaler and does not consume any recreational or therapy-related drugs. He worked as a bank clerk previously. He is married with 5 children, whom are all healthy.

On examination, he was alert with a body weight of 75 kilograms. He demonstrated a Charlson comorbidity index (CCI) score of 4 (low risk) with an Eastern Cooperative Oncology group (ECOG) performance status of 0 (fully active). His blood pressure was 140/70 with a pulse rate of 96 beats per minute. He was afebrile. Visible cutaneous bruising was evident. His cardiovascular and respiratory system examinations were unremarkable. There was no palpable organomegaly or lymphadenopathy.
A complete blood count revealed severe pancytopenia. The blood parameters are tabulated in Table 1.

The peripheral blood film revealed erythrocyte aniso-poikilocytosis and severe pancytopenia. The bone marrow aspiration (Figure 1A) was apaticulate and markedly hypocellular. No abnormal cells were seen. The bone marrow trephine biopsy (Figure 1B) revealed a hypocellular marrow which was replaced mainly with nonhematopoietic tissue such as fat. Flow cytometry analysis did not show any evidence of leukemia. Cytogenetic studies using Giemsa banding technique revealed -Y and trisomy 8 abnormalities. Multiparameter flow cytometry and Fluorescent aerolysin (FLAER) of erythrocytes, polymorphonuclear neutrophils, and monocytes did not detect any paroxysmal nocturnal hemoglobinuria (PNH) clone. Whole-body CT imaging did not reveal any organomegaly or lymphadenopathy.

He was diagnosed with very severe idiopathic aplastic anemia (based on Camitta criteria, 1976).

In view of his advanced age, he was not suitable for an allogeneic stem cell transplant. He was treated with triple therapy consisting of Intravenous equine Antithymocyte globulin (ATGAM) 40 mg/kg for 4 days, oral ciclosporin A (CsA) 75 mg twice daily (total daily dose of 2 mg/kg per body weight) and concomitant upfront subcutaneous granulocyte-colony stimulating factor (G-CSF) 300 mcg once daily. Serum sickness prophylaxis in the form of intravenous methylprednisolone 1 mg/kg 30 minutes before and after the ATGAM was also administered. The oral CsA was titrated slowly to a maximum of 125 mg twice daily (total daily dose of 3 mg/kg per body weight) in view of the patient’s age and risk of nephrotoxicity in the elderly. He was also given a thrombopoietin receptor agonist, oral eltrombopag 50 mg once daily, and triple antimicrobial prophylaxis (acyclovir, trimethoprim/sulfamethoxazole, and fluconazole). However, he developed severe pneumonia and sepsis on Day 8 of ATGAM therapy which necessitated oxygen support. The chest radiograph (Figure 2) showed diffuse bilateral interstitial and nodular consolidation. The family opted for palliation. He succumbed to his illness on Day 10 of treatment.

### DISCUSSION

We describe an interesting case of idiopathic very severe aplastic anemia (VSAA) in an 80-year-old man who did not have any obvious secondary risk factors. VSAA is defined as bone marrow hypoplasia < 30% on a bone marrow trephine biopsy AND two of the three following criteria: polymorphonuclear

| Blood parameters     | Value (normal range with SI unit)               |
|----------------------|------------------------------------------------|
| Hemoglobin           | 5.5 (1.3-16.5 g/dL)                             |
| Total White Cell count| 0.9 (4-10 × 10⁹/L)                             |
| Absolute neutrophil count (ANC) | 0.1 (2-7 × 10⁹/L)   |
| Platelet             | 15 (150-400 × 10⁹/L)                           |
| Lactate Dehydrogenase (LDH) | 150 (140-280 U/L)    |
| Creatinine           | 65 (60-90 umol/L)                              |
| Alanine Transaminase | 26 (0-40 U/L)                                  |
| B12                  | 350 (200-600 ng/mL)                            |
| Folate               | 12 (2-10 ng/mL)                                |
| Cytomegalovirus IgM/IgG | Not detected                                 |
| Epstein Barr IgM/IgG | Not detected                                  |
| Parvovirus IgM/IgG   | Not detected                                  |
| HepBsAg              | Not reactive                                  |
| Anti-HepC            | Not reactive                                  |
| Anti-HIV-1,2         | Not reactive                                  |
| Antinuclear antibody (ANA) | Not reactive                        |

**(A)** Bone marrow aspiration is apaticulate and markedly hypocellular. No abnormal cells were seen. **(B)** Bone marrow trephine biopsy shows a hypocellular marrow which was replaced mainly with nonhematopoietic tissue such as fat.
neutrophils < 0.2 \times 10^9/L, platelets < 20 \times 10^9/L, or absolute reticulocyte count < 20 \times 10^9/L. \textsuperscript{5} Over the age of 60 AA, 6 in 10 patients are women as opposed to a higher male incidence in the younger age-group.\textsuperscript{6}

AA in the elderly may demonstrate a variety of molecular mutations. Next-generation sequencing (NGS) by Yoshizato et al on 439 patients with AA demonstrated no significant relationship between the presence of molecular mutations and response to IST.\textsuperscript{7} However, on individual gene assessment, molecular mutations in BCOR, BCORL1, and PIGA were associated with a better response to IST while mutations in DNMT3A and ASXL1 were linked to an adverse outcome.\textsuperscript{7}

Cytogenetic abnormalities are seen in 4%-5% of aplastic anemia patients over the age of 60.\textsuperscript{8} A French nationwide survey study of 88 aplastic anemia patients over the age of 60 demonstrated 8% of these patients had cytogenetic abnormalities. The common cytogenetic abnormalities encountered were Y deletions, trisomy 8, 13p deletion, 4q deletion, chromosome 14 aberrations, and one split of IgH locus.\textsuperscript{9} Our patient in this case revealed -Y and trisomy 8 cytogenetic abnormalities which were consistent with findings found in the literature.

High frequency of HLA-DR2 and its serologic spilt HLA-DR15 are overexpressed in AA and hypoplastic MDS. Saunthararajah et al studied two cohorts at the National Institute of Health (NIH) which consisted of 148 patients with severe AA in cohort 1 and 2609 patients with severe AA who received allogeneic SCT in cohort 2. Thirty-two of forty-seven HLA-DR15 positive AA and thirty-one of fifty-two HLA-DR15 negative AA patients responded to the combination ATG-CsA therapy.\textsuperscript{10} Hence, the presence of HLA-DR15 overexpression does not predict a response to IST in AA.\textsuperscript{10}

Several other biomarkers may contribute to responsiveness of immunosuppressive therapy (IST) in elderly AA. Shorter duration of AA, younger age at diagnosis, a higher absolute neutrophil count, a higher absolute lymphocyte count, a higher baseline platelet count, higher CsA levels during the first 2 weeks of commencement of IST, longer telomere length, positive minor PNH clone, lower thrombopoietin (TPO) levels, and increased IFN-gamma expression in the bone marrow indicate better response to IST.\textsuperscript{11}

Telomere shortens with age and is a marker of an aging process. Significant abnormal shortening of telomeres of bone marrow nucleated cells have been seen in elderly AA.\textsuperscript{12} Telomeres are structures with tandem DNA repeats of 5’-TTAGGG-3’.\textsuperscript{12} Increased oxidative and hematopoietic stress contributes to the abnormal shortening of telomeres which in turn lead to genomic instability in AA.\textsuperscript{12}

The Dutch Society of Hematology national guidelines recommends a combination of equine ATG 40mg/kg daily for 4 days, oral CsA therapy, and subcutaneous G-CSF as first-line therapy in patients with severe AA not suitable for allogeneic hematopoietic stem cell transplantation.\textsuperscript{13,14} This combination incorporating G-CSF is efficacious as it allows quick neutrophil recovery and identifies early nonresponders. The use of G-CSF was not associated with any increase in clonal transformation.\textsuperscript{13} The overall survival (OS) at 6 and 12 months in elderly patients (aged 60 years and above) treated with ATG-CsA combination therapy was 96% and 88%, respectively, as compared to only 35% with CsA alone, 22% with eltrombopag alone, and 21% with androgen alone.\textsuperscript{14,15} The overall response rates (ORR) in patients over 70 years receiving ATG-CsA was 81%.\textsuperscript{15} Patients aged more than 70 receiving ATG-CsA did not appear to suffer from any additional complications than the younger age group and tolerated the treatment well.\textsuperscript{15} Among the common complications seen in this subgroup of elderly AA patients (>70 years old) who received ATG-CsA combination therapy were infections (88%), followed by acute kidney injury (50%), cardiovascular complications (31%), hemorrhagic manifestations (19%), and neurological complications (13%).\textsuperscript{15} Reducing the dose of ATG without administering CsA in elderly AA was associated with a lower risk of treatment toxicity but the response was dismal as only 1 out of the 14 elderly patients achieved a partial hematological response in a British multicentre study.\textsuperscript{16} It is interesting to note that the addition of oral eltrombopag at a median maximum dose of 150 mg daily (50-300 mg) to standard ATG-CsA combination therapy in newly diagnosed severe AA with a median age of 47 (19-66), produced an ORR of 90% (trilineage response: 60%, neutrophil response: 20%, platelet response: 30%) at 12 weeks of therapy.\textsuperscript{17} Eltrombopag is well tolerated in the elderly. Besides, sex hormones such as oral testosterone 40 mg/day for 5 days per week demonstrated a 59% ORR in patients with persistent cytopenia after ATG-CsA therapy.\textsuperscript{18} Combination of CsA and androgens would be the treatment of choice for frail patients above the age of 70 who are not suitable for the more intensive ATG-CsA therapy.\textsuperscript{18}

![Chest radiograph shows diffuse bilateral interstitial and nodular consolidation](image-url)
**CONCLUSION**

In summary, we report a case of very severe aplastic anemia in an 80-year-old man who had a poor outcome with standard treatment. His adverse risk factors which contributed to his poor disease outcome were probably advanced age, severe pancytopenia at diagnosis, delay in seeking treatment, absence of a minor PNH clone, and therapy-related complications. Age on its own should not be a contraindication to treat elderly severe AA patients with combination ATG-CsA therapy.

**GUARANTOR**

Ganesh Kasinathan is the guarantor of this manuscript.

**CONSENT**

Written informed consent was obtained from the patient for publication of this case report and the accompanying images.

**CONFLICT OF INTEREST**

The authors declare there are no conflicting interests.

**AUTHOR CONTRIBUTIONS**

GK: analyzed the data, designed the paper, and contributed to the writing of the manuscript. LBS and J.S: made critical revisions and approved the final manuscript.

**ETHICAL APPROVAL**

Ethical approval is not required as this is not a clinical trial.

**DATA AVAILABILITY STATEMENT**

The data used and analyzed during this study are available from the corresponding author on request.

**ORCID**

Ganesh Kasinathan https://orcid.org/0000-0002-7489-9261

**REFERENCES**

1. Risitano AM, Maciejewski JP, Green S, et al. In-vivo dominant immune responses in aplastic anemia: molecular tracking of putatively pathogenetic T-cell clones by TCR beta-CDR3 sequencing. *Lancet*. 2004;364:355-364.
2. Issaragrisil S. Thai Aplastic Anemia Study Group. Epidemiology of aplastic anemia in Thailand. *Int J Hematol*. 1999;70:137-140.
3. Young NS. Aplastic anemia. *The N Engl J Med*. 2018;379(17):1643-1656.
4. Montane E, Ibanez L, Vidal X, et al. Epidemiology of aplastic anemia: a prospective multicenter study. *Haematologica*. 2008;93(4):518-523.
5. Camitta BM, Thomas ED, Nathan DG, et al. Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. *Blood*. 1976;48(1):63-70.
6. Tichelli A, Marsh J. Treatment of aplastic anemia in elderly patients aged > 60 years. *Bone Marrow Transplant*. 2013;48:180-182.
7. Yoshizato T, Dumitriu B, Hosokawa K, et al. Somatic mutations and clonal hematopoiesis in aplastic anemia. *N Engl J Med*. 2015;373(1):35-47.
8. Kim SY, Lee JW, Lee SE, et al. The characteristics and clinical outcome of adult patients with aplastic anemia and abnormal cytogenetics at diagnosis. *Genes Chromosomes Cancer*. 2010;49(9):844-850.
9. Maciejewski JP, Risitano A, Sloand EM, et al. Distinct clinical outcomes for cytogenetic abnormalities evolving from aplastic anemia. *Blood*. 2002;99:3129-3135.
10. Saunthararajah Y, Nakamura R, Nam JM, et al. HLA-DR15 (DR2) is overexpressed in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. *Blood*. 2002;100(5):1570-1574.
11. Narita A, Kojima S. Biomarkers for predicting clinical response to immunosuppressive therapy in aplastic anemia. *Int J Haematol*. 2016;104:153-158.
12. Wang C, Zhang T, Wang Y, et al. The shortening telomere length of T-lymphocytes maybe associated with hyper-function in severe aplastic anemia. *Mol Med Rep*. 2018;17(1):1015-1021.
13. Tichelli A, Schrezenmeier H, Socie G, et al. A randomised controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow transplantation. *Blood*. 2011;117(17):4434-4441.
14. Tjon JM-L, de Groot MR, Sypkens SMA, et al. Short-term efficacy and safety of antithymocyte globulin treatment in elderly patients with acquired aplastic anemia. *Br J Haematol*. 2016;180(3):459-462.
15. Contejean A, Resche-Rigon M, Tamburini J, et al. Aplastic anemia in the elderly: a nationwide survey on behalf of the French Reference Center for Aplastic Anemia. *Haematologica*. 2018;104(2):256-262.
16. Killick SB, Cavenagh JD, Davies JK, et al. Low dose antithymocyte globulin for the treatment of older patients with aplastic anemia. *Leuk Res*. 2006;30(12):1517-1520.
17. Hwang YY, Harinder G, Chan TSY, et al. Eltrombopag in the management of aplastic anemia: real world experience in a non-trial setting. *Hematology*. 2018;23(7):399-404.
18. Bacigalupo A. How I treat aplastic anemia. *Blood*. 2017;129(11):1428-1436.

**How to cite this article:** Kasinathan G, Lee BS, Sathar J. Very severe aplastic anemia in an 80-year-old man. *Clin Case Rep*. 2021;9:1330–1333. https://doi.org/10.1002/ccr3.3757